跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
DUOBRII - Health Canada Drug Approval Details
Approvals
/
Health Canada
/
DUOBRII
Authorized
STANDARD
DUOBRII
bausch health, canada inc.
🇨🇦 Health Canada
Approval Date
Jul 4, 2025
Approval ID
ff410c4e57b293cf
Company
bausch health, canada inc.
Type
Standard
Approval Details
Approval Id
ff410c4e57b293cf
Drug Approval Canada Name
DUOBRII
Product Name
DUOBRII
Status
Marketed
Status Date
2020-08-04
Original Market Date
2020-08-04
Din
02499967
Drug Class
Human
Dosage Form
Lotion
Route Of Administration
Topical
Schedule
Prescription
Ahfs
84:92.00
Atc Original
D05AX05 TAZAROTENE
Atc Name
d 05 ax 05
Aig Number
0262297001
Company Name
bausch health, canada inc.
Company Address
2150 Boul. St-Elzear Ouest, Laval, Quebec, Canada, H7L 4A8
Active Ingredients
TAZAROTENE
0.045 % / W/W
HALOBETASOL PROPIONATE
0.01 % / W/W
Authorized
Quick Info
Agency
Health Canada
Country
🇨🇦
Approval Date
Jul 4, 2025
Approval ID
ff410c4e57b293cf
Type
Standard
Back to Health Canada Approvals